Cancer Biology of Retinoblastoma

Retinoblastoma Clinical Trial

Official title:

Cancer Biology of Retinoblastoma

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01642823
• Other study ID #: PEDSEYE0002
• Status: Terminated
• Phase: N/A
• First received: July 11, 2012
• Last updated: March 2, 2017
• Start date: July 2012
• Est. completion date: December 2015

Study information

• Verified date: March 2017
• Source: Stanford University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Many children with the childhood cancer, Retinoblastoma, have surgery to remove the tumor and sometimes the entire eye. The purpose of this study is to collect the extra tissue from patients who undergo tumor removal for laboratory experiments that will help us understand not only what occurs in retinoblastoma cells but also how cells normally function. Some of these studies will include an evaluation of how cells control the way that genes are expressed, how cells "know" to become retinal cells, how cells remain retinal cells, how cells lose their identity as retinal cells, what changes make retinoblastoma cells different from normal retinal cells, and what changes make some retinoblastomas worse than others.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 8
• Est. completion date: December 2015
• Est. primary completion date: December 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 5 Years

Eligibility

Inclusion Criteria:

• Patient must have retinoblastoma

• Patient must be receiving biopsy, partial surgical excision of the tumor, complete excision of the tumor, or enucleation of the eye as part of their standard care.

• Parental consent

Exclusion Criteria:

• Diagnosis other than Retinoblastoma

• No surgical sampling of tumor is planned as part of standard care

• Parental preference to not participate.

Related Conditions & MeSH terms

• Retinoblastoma

Locations

Country	Name	City	State
Guatemala	Unidad Nacional de Oncologia Pediatrica	Guatemala
United States	Stanford University Cancer Institute	Stanford	California

Sponsors (1)

Lead Sponsor	Collaborator
Stanford University

Countries where clinical trial is conducted

United States,  Guatemala, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in efficiency of reprogramming in cells with "naturally occurring" retinoblastoma mutations	Comparison of number of reprogramming events (defined by colony formation assay and normalized for number of cell plated) as well as the time to reprogramming.	After appropriate time, e.g., 7, 10, 14 days after reprogramming